Paul Hastings Represents Sponsor in Livzon Pharmaceuticals B to H-share Listing

January 17, 2014

Hong Kong (January 16, 2014) - Paul Hastings, a leading global law firm, announced today that the firm represented Guosen Securities (HK) Capital Company Limited as the sponsor in the listing of Livzon Pharmaceutical Group Inc.’s (“Livzon Pharmaceutical”) H-shares converted from B-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction.

Livzon Pharmaceutical is a comprehensive pharmaceutical enterprise integrating research & development, production and sales of pharmaceutical products and is already listed on the Shenzhen Stock Exchange.

The successful closing of this transaction marks the second B to H-share conversion – making Paul Hastings the only international law firm to advise on all of the B to H-share projects launched in the market to date.

Paul Hastings previously advised China International Marine Containers (Group) Co., Ltd., a leading global equipment and solutions provider in the logistics and energy industries, on its landmark listing of H-shares converted from B-shares on the Main Board of the Hong Kong Stock Exchange by way of introduction.

The Paul Hastings team was led by Raymond Li, partner and Chair of Greater China, and capital markets partners Sammy Li and Zhaoyu Ren, with support from associates Jason Wang and Ke Zhu.

Paul Hastings is a leading global law firm with offices in Asia, Europe, and the United States. We provide innovative legal solutions to financial institutions and Fortune 500 companies. Please visit www.paulhastings.com for more information.